Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Subscribe To Our Newsletter & Stay Updated
